Mechanism Of Action

PROVENGE® (sipuleucel-T) immunotherapy is designed to target and attack prostate cancer cells

PROVENGE is the first and only FDA-approved immunotherapy for asymptomatic or minimally symptomatic mCRPC

Targeted Mechanism of Action1

The recombinant antigen used to make PROVENGE is PAP-GM-CSF. It consists of prostatic acid phosphatase (PAP), an antigen expressed in more than 95% of prostate cancers, and granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-cell activator.1